Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment
NCT ID: NCT00647179
Last Updated: 2017-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
27 participants
OBSERVATIONAL
2008-02-29
2016-12-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Patients recently diagnosed with acromegaly
Transsphenoidal adenomectomy
Surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transsphenoidal adenomectomy
Surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18 and 70
* Recently diagnosed with acromegaly
Exclusion Criteria
* Uncontrolled hypertension
* Known cerebrovascular disease
* Proliferative retinopatia
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aarhus University Hospital
OTHER
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jens Otto L. Jørgensen, Professor MD
Role: PRINCIPAL_INVESTIGATOR
Aarhus University Hospital, Department of Endocrinology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Endocrinology, Aarhus University Hospital
Aarhus C, Aarhus, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Arlien-Soborg MC, Grondahl C, Baek A, Dal J, Madsen M, Hogild ML, Pedersen SB, Bjerre M, Jorgensen JOL. Fibroblast Activation Protein is a GH Target: A Prospective Study of Patients with Acromegaly Before and After Treatment. J Clin Endocrinol Metab. 2020 Jan 1;105(1):dgz033. doi: 10.1210/clinem/dgz033.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M-20070130
Identifier Type: -
Identifier Source: secondary_id
MM-ISA-20070130
Identifier Type: -
Identifier Source: org_study_id